Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153

Results For "ET"

10697 News Found

Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023
Policy | January 05, 2023

Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023

The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.


PharmaEssentia sets up a new R&D facility in the Boston Area
News | January 05, 2023

PharmaEssentia sets up a new R&D facility in the Boston Area

The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation


Themis Medicare launches Lenzetto for treatment of menopausal symptoms
News | January 04, 2023

Themis Medicare launches Lenzetto for treatment of menopausal symptoms

It ensures sufficient serum estradiol levels to alleviate menopausal symptoms


Zydus receives final approval from USFDA for Triazolam Tablets
Drug Approval | December 31, 2022

Zydus receives final approval from USFDA for Triazolam Tablets

Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)


InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
Drug Approval | December 31, 2022

InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong

Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency


Cipla EU to invest € 15 million in Ethris
News | December 30, 2022

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies


Mandaviya and Puri hail MoU between IndianOil and Central TB Division for states of UP and Chhattisgarh
Policy | December 29, 2022

Mandaviya and Puri hail MoU between IndianOil and Central TB Division for states of UP and Chhattisgarh

This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep


Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
News | December 28, 2022

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze


MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
Drug Approval | December 27, 2022

MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes

MindRank expects to initiate a Phase I safety study in the first quarter of 2023.


Hetero's COVID-19 oral drug gets WHO prequalification
News | December 27, 2022

Hetero's COVID-19 oral drug gets WHO prequalification

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission